Guardant Health’s Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer screening (CRC) will be covered in EviCore by Evernorth clinical guidelines effective January 1, 2027, per ACS guidelines. EviCore is a Cigna-owned company and the…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.